IL278642A - - Google Patents

Info

Publication number
IL278642A
IL278642A IL27864220A IL27864220A IL278642A IL 278642 A IL278642 A IL 278642A IL 27864220 A IL27864220 A IL 27864220A IL 27864220 A IL27864220 A IL 27864220A IL 278642 A IL278642 A IL 278642A
Authority
IL
Israel
Application number
IL27864220A
Other languages
English (en)
Other versions
IL278642B2 (en
IL278642B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL278642A publication Critical patent/IL278642A/en
Publication of IL278642B1 publication Critical patent/IL278642B1/en
Publication of IL278642B2 publication Critical patent/IL278642B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
IL278642A 2018-05-11 2019-05-10 Purine inhibitors IL278642B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862670050P 2018-05-11 2018-05-11
PCT/EP2019/062098 WO2019215341A1 (en) 2018-05-11 2019-05-10 Furin inhibitors

Publications (3)

Publication Number Publication Date
IL278642A true IL278642A (cg-RX-API-DMAC7.html) 2020-12-31
IL278642B1 IL278642B1 (en) 2023-06-01
IL278642B2 IL278642B2 (en) 2023-10-01

Family

ID=66597541

Family Applications (2)

Application Number Title Priority Date Filing Date
IL302997A IL302997B2 (en) 2018-05-11 2019-05-10 Purine inhibitors
IL278642A IL278642B2 (en) 2018-05-11 2019-05-10 Purine inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL302997A IL302997B2 (en) 2018-05-11 2019-05-10 Purine inhibitors

Country Status (12)

Country Link
US (1) US11773078B2 (cg-RX-API-DMAC7.html)
EP (1) EP3790871B1 (cg-RX-API-DMAC7.html)
JP (1) JP7350061B2 (cg-RX-API-DMAC7.html)
KR (1) KR102823187B1 (cg-RX-API-DMAC7.html)
CN (1) CN112384509B (cg-RX-API-DMAC7.html)
AU (1) AU2019267166C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020022961A2 (cg-RX-API-DMAC7.html)
CA (1) CA3099863A1 (cg-RX-API-DMAC7.html)
IL (2) IL302997B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020012034A (cg-RX-API-DMAC7.html)
SG (1) SG11202010914YA (cg-RX-API-DMAC7.html)
WO (1) WO2019215341A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202010914YA (en) 2018-05-11 2020-12-30 Glaxosmithkline Ip Dev Ltd Furin inhibitors
WO2021097002A1 (en) * 2019-11-12 2021-05-20 Bp Asset V, Inc. Use of pyridyloxypyrimidines for treating infectious diseases
WO2021097008A1 (en) * 2019-11-12 2021-05-20 Bp Asset V, Inc. Use of pyridyloxypyridines for treating infectious diseases
JP2023503852A (ja) * 2019-11-12 2023-02-01 ビーピー アセット ヴイ,インコーポレーテッド 感染症を処置するための低分子フーリン阻害剤
JP2023521032A (ja) * 2020-04-02 2023-05-23 ビーピー アセット ヴイ,インコーポレーテッド コロナウイルス感染症を処置するためのフーリンインヒビター
FR3110345B1 (fr) 2020-05-21 2024-03-29 Agence Francaise Pour Le Dev D’Al Ula Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques.
CN117222410A (zh) * 2021-02-03 2023-12-12 Bp资产V股份有限公司 用于吸入的弗林蛋白酶抑制剂的制剂
CN114853640A (zh) * 2022-05-12 2022-08-05 马鞍山昂扬新材料科技有限公司 2-溴乙基磺酸钠的制备方法
EP4594312A1 (en) * 2022-09-29 2025-08-06 BP Asset V, Inc. 4-((2-(3,5-dichlorophenyl)-6-((pyrimidin-5-yl)oxy)pyridin-4-yl)methyl)piperazine derivatives as furin inhibitors and uses thereof
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung
CN119119096B (zh) * 2024-09-09 2025-09-16 郑州药领医药科技有限公司 一种4-((4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)甲基)哌啶-1-甲酸叔丁酯的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147019A (en) 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
DK2316831T3 (da) 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
WO2005047268A2 (en) 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
EP1799244A4 (en) * 2004-07-23 2010-06-09 Smith Judith INHIBITORS OF FURINE
WO2006031852A1 (en) * 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2687024A1 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
KR101247840B1 (ko) * 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
HRP20171587T1 (hr) 2010-10-18 2017-12-01 Cerenis Therapeutics Holding Sa Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola
WO2013138665A1 (en) * 2012-03-16 2013-09-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
US20150051138A1 (en) 2012-03-16 2015-02-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
EP2884982B1 (en) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US10150742B2 (en) 2013-03-15 2018-12-11 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
US10766860B2 (en) * 2015-03-06 2020-09-08 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
CN107441094B (zh) 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
SG11202010914YA (en) 2018-05-11 2020-12-30 Glaxosmithkline Ip Dev Ltd Furin inhibitors
JP2023503852A (ja) 2019-11-12 2023-02-01 ビーピー アセット ヴイ,インコーポレーテッド 感染症を処置するための低分子フーリン阻害剤

Also Published As

Publication number Publication date
SG11202010914YA (en) 2020-12-30
IL302997B1 (en) 2024-04-01
CN112384509B (zh) 2024-04-30
CN112384509A (zh) 2021-02-19
IL302997A (en) 2023-07-01
MX2020012034A (es) 2021-04-12
JP7350061B2 (ja) 2023-10-02
EP3790871C0 (en) 2024-01-24
IL278642B2 (en) 2023-10-01
US20220315556A1 (en) 2022-10-06
EP3790871B1 (en) 2024-01-24
AU2019267166B2 (en) 2023-06-15
EP3790871A1 (en) 2021-03-17
AU2019267166A1 (en) 2020-11-26
KR102823187B1 (ko) 2025-06-20
KR20210021298A (ko) 2021-02-25
WO2019215341A1 (en) 2019-11-14
JP2021523941A (ja) 2021-09-09
US11773078B2 (en) 2023-10-03
CA3099863A1 (en) 2019-11-14
BR112020022961A2 (pt) 2021-02-17
IL278642B1 (en) 2023-06-01
AU2019267166C1 (en) 2023-11-30
IL302997B2 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
BR112021000792B8 (cg-RX-API-DMAC7.html)
AT524874A5 (cg-RX-API-DMAC7.html)
AT524834A2 (cg-RX-API-DMAC7.html)
AU2018438767B1 (cg-RX-API-DMAC7.html)
AT521543A3 (cg-RX-API-DMAC7.html)
AT524961A5 (cg-RX-API-DMAC7.html)
BR102019026286B1 (pt) Método e aparelho para o avanço de produtos a serem moldados
BR102019025884B1 (pt) Sistema de segurança aprimorado para máquinas de operação de autopropulsão
BR102019023514B1 (pt) Método para determinar a massa de ar preso em cada cilindro de um motor a combustão interna
BR112020016338B1 (pt) Dispositivo para tratamento de tecido corporal
BR112021004021B1 (pt) Método e sistema para produzir um resíduo de rejeitos empilhável
BR112021001186B1 (pt) Aparelho para o tratamento de celulite para tratar expressões de celulite na pele de um paciente associadas a um local de tratamento de septos
BR112020023795B1 (pt) Composição de recheio para um produto de chocolate à base de gordura, e seus métodos de produção
BR112021000922B1 (pt) Tela de filtro, e, método para purificar água de alimentação
BR112020026077B1 (pt) Recipiente com estrutura encaixável
BR112020026721B1 (pt) Aparelho de moldagem para modar uma folha de um material contendo alcaloides
BR102019012845B1 (pt) Montagens de guia de entrada de piso de compartimento de carga retráteis para carregamentos paletizados em aeronaves de carga e aeronave e carga
BR112020023832B1 (pt) Amostra de calibração de sistemas de análise multiespectral e método para calibração de sistemas de análise multiespectral
BR112020024987B1 (pt) Método, montagem e sistema para prover uma estrutura de base, método industrial, e, braço mecânico
BR112020023823B1 (pt) Distribuidor
BR112020022482B1 (pt) Composição, anticorpo anti-cd24, anticorpo biespecífico e receptor de antígeno quimérico
BR112020022658B1 (pt) Método para estimar um nível de pressão sonora, sistema de fone de ouvido, fone de ouvido e uso do fone de ouvido
BR112020022516B1 (pt) Processo para degomagem enzimática de óleo
BR112020021042B1 (pt) Compostos de carboxamidas bicíclicas, composição farmacêutica e uso das mesmas
BR112020020812B1 (pt) Composições de tratamento de superfícies duras, seu uso, método para proporcionar ação antimicrobiana residual e substrato relacionado